Week in Review: iCarbonX Closes $155 Million Series A at $1 Billion Valuation

iCarbonX, the Shenzhen AI/big healthcare data startup, completed a $155 million Series A funding that values the six-month-old company at $1 billion; Shanghai's Hua Medicine closed a $50 million Series C funding round that will fund a Phase III trial of its GKA treatment for type 2 diabetes; Yabao Pharma of Shanghai partnered with New Jersey's Salus Pharma to develop high-barrier-to-entry generic drugs; Venus Medtech of Hangzhou acquired next-gen cardiac valve technology from Germany's Transcatheter, Immune Therapeutics, a Florida biopharma, signed a binding LOI to acquire a CAR-T therapy developed in China; Beijing Strong Biotechnologies granted Abbott Labs rights to its clinical chemistry testing products; BeiGene, a Beijing oncology company, reported positive initial data from a continuing Phase I trial of a BRAF-targeted cancer drug; and Ascenta Pharma of Guangzhou presented encouraging preclinical results of its AKR1C3 drug to an American Cancer Research meeting. More details.... Stock Symbols: (SHA: 600351) (OTCQB: IMUN) (SHE: 300406) (NYSE: ABT) (NSDQ: BGNE) Share this with colleagues: // //